Oncothyreon Announces Presentations at Upcoming Conferences in March 2011
SEATTLE, March 1 /PRNewswire-FirstCall/ - Oncothyreon Inc. (Nasdaq: ONTY) announced today that the company will be presenting at the following industry and investor conferences during March:
- 11th Annual Life Science Innovation Northwest Conference: Julie Eastland, Oncothyreon's Chief Financial Officer, will present at this life sciences conference in Seattle on Wednesday, March 2 at 1:45 p.m. Pacific Time.
- 22nd Annual Cancer Progress Conference: Robert Kirkman, M.D., Oncothyreon's President and Chief Executive Officer, will participate on a panel of oncology experts during this conference in New York. Dr. Kirkman's panel/session - Immuno-Oncology - is scheduled for Tuesday, March 8 at 11:45 a.m. Eastern Time.
- Cowen and Company 31st Annual Health Care Conference: Dr. Kirkman will present at the Cowen conference in Boston on Wednesday, March 9 at 11 a.m. Eastern Time. A live and archived webcast of all of the presentation will be accessible by visiting the Oncothyreon website www.oncothyreon.com under the "News & Events" section.
- Roth 23rd Annual OC Growth Stock Conference: Dr. Kirkman will join a panel discussion - Hot Targets in Oncology and the Reimbursement Landscape - at this conference in Dana Point, Calif., on Monday, March 14 at 11 a.m. Pacific Time. Dr. Kirkman will also give a corporate presentation on Monday, March 14 at 1:30 p.m. Pacific Time. A live and archived webcast of the corporate presentation will be accessible by visiting the Oncothyreon website www.oncothyreon.com under the "News & Events" section.
About Oncothyreon
Oncothyreon is a biotechnology company specializing in the development of innovative therapeutic products for the treatment of cancer. Oncothyreon's goal is to develop and commercialize novel synthetic vaccines and targeted small molecules that have the potential to improve the lives and outcomes of cancer patients. For more information, visit www.oncothyreon.com.
Additional Information
Additional information relating to Oncothyreon can be found on U.S. EDGAR at www.sec.gov.
SOURCE Oncothyreon Inc.
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
440k+
Newsrooms &
Influencers
Newsrooms &
Influencers
9k+
Digital Media
Outlets
Digital Media
Outlets
270k+
Journalists
Opted In
Journalists
Opted In
Share this article